当前位置： SCI文献检索 > REVISTA MEDICA DE CHILE期刊下所有文献 > [Response rates to first-line treatment in eligible patients to autologous stem transplantation in Chile].

[Response rates to first-line treatment in eligible patients to autologous stem transplantation in Chile].

Abstract：

:Background The treatment of choice of newly diagnosed multiple myeloma (NDMM) is an induction with proteasome inhibitors followed autologous stem cell transplantation (HSCT). Since 2013, the treatment of these patients in the public system is based on CTD (cyclophosphamide, thalidomide, and dexamethasone). Aim To evaluate the response rates achieved with CTD, and the results of HSCT in patients with NDMM in the public setting. Material and Methods Data from patients considered as candidates for HSCT from different centers of the National Adult Antineoplastic Drug Program (PANDA, for its acronym in Spanish), diagnosed between 2013 and 2017, was analyzed. The response to treatment of first and second lines of treatment was evaluated, in addition to the results of HSCT. An optimal Response was defined as the sum of strict complete remission, complete remission and very good partial response (sCR, CR and VGPR). Results One hundred and seventy-seven patients were analyzed, 54% women, and 53% with IgG multiple myeloma. Information about the international staging system was retrieved in 127 patients (71%). Seventeen percent were ISS I, 22% in ISS II and 32% ISS III. CTD was used as first treatment in 106 patients (60%), and cyclophosphamide, bortezomib and dexamethasone (CyBorD) in 13 (7%). As first line, CTD had an overall response of 50.9%, and CyBorD of 76.9%. Thirty patients were treated with bortezomib as second line treatment. Forty patients (22%) underwent HSCT. The 5-year Overall Survival (OS) in transplanted patients and non-transplanted patients was 100 and 62% respectively (p < 0.01). Conclusions The response rate achieved by CTD in these patients is suboptimal. The response to CyBorD was better.

journal_name

Rev Med Chil

journal_title

Revista medica de Chile

authors

Peña C,Rojas-Vallejos J,Espinoza M,Donoso J,Soto P,Cardemil D,Aranda S,Contreras C,Vergara CG,LA Rocca G,Osorio R,López-Vidal H,Chandía M,Rojas C

doi

10.4067/S0034-98872019001201561

subject

Has Abstract

pub_date

2019-12-01 00:00:00

pages

1561-1568

issue

eissn

0034-9887

issn

0717-6163

pii

S0034-98872019001201561

journal_volume

147

pub_type

杂志文章,多中心研究

在线工具

[Response rates to first-line treatment in eligible patients to autologous stem transplantation in Chile].